The role of mutation status of the epidermal growth factor receptor gene in advanced non-small cell lung cancer

Medicina (Lithuania)

Volumn 48, Issue 4, 2012, Pages 175-181

  Vaguliene, Neringa ^a   Žemaitis, Marius ^a   Šarauskas, Valdas ^a   Vitkauskiene, Astra ^a   Miliauskas, Skaidrius ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

EGFR mutations; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EID: 84866606521     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina48040025     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Blackhall FM, Shepherd FA, Albain KS. Improving survival and reducing toxicity with chemotherapy in advanced non small cell lung cancer: a realistic goal? Treat Respir Med 2005;4:71-84.
3. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with beva-cizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
5. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;28:5311-20.
6. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carbopla-tin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicen-tre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
8. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-67.
9. Jimeno A, Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta 2006;1766:217-29.
10. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clin-ical response to gefitinib therapy. Science 2004;304:1497-500.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Oki-moto RA, Brannigan BW, et al. Activatig mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
12. Pao W, Miller V, Zakowsky M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancer from "never smokers" and are associated with sen-sitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
13. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancer. Int J Cancer 2006;118:257-62.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancer. J Natl Cancer Inst 2005;97:339-46.
15. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps of sensitivity to EGFR-TKI treatment in patients with advanced NSCLC. Statement of Conflict of Interest The authors state no conflict of interest. C, et al. Spanish Lung Cancer Group. Screening for epi-dermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67.
16. Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogeno-mics 2009;10:59-68.
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
18. Sobin LH, Gospodarowicz MK, Wittekind Ch. (Interna-tional Union Against Cancer). The TNM Classification of Malignant Tumours. 7th ed. Oxford: Wiley-Blackwell; 2009.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sar-gent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RESIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
20. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65.
21. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemo-therapy (EURTAC) phase III randomized trial. ASCO 2011; Abstract 7503.
22. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006;11:190-8.
23. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Ires-sa") on an expanded access study. Lung Cancer 2004;44: 221-30.
24. Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 2006;7:S138-44.
25. Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 2009;133:470-7.
26. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic sub-type suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-27.
27. Ohtsuka K, Ohnishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenos-quamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007;109:741-50.
28. Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. Am J Clin Pathol 2011;135:783-9.
29. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geis-inger K, Yatabe Y. International association for the study of lung cancer/American Thoracic Society/European Res-piratory Society: international multidisciplinary classifica-tion of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011;8:381-5.
30. Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chroma-tography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2010;116:4215-32.
31. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small-cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44.
32. Jacman DM, Yeap BY, Sequist LV, Lindeman N, Holomes AJ, Joshi VA, et al. Exon 19 deletion mutation of epider-mal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-14.